Neurological manifestations in patients with VEXAS syndrome

• Published in: Journal of neurology 2025-02, Vol.272 (2), p.181
• Main Authors: Bert-Marcaz, Charlotte, Fortanier, Étienne, Briantais, Antoine, Faucher, Benoit, Bourguiba, Rim, Swiader, Laure, Schleinitz, Nicolas, Corazza, Giovanni, Jean, Rodolphe, Bigot, Adrien, Marianetti-Guingel, Paola, Kostine, Marie, Outh, Roderau, Dieudonné, Yannick, Lazaro, Estibaliz, Vial, Guillaume, Palat, Sylvain, Frachet, Simon, De Almeida Chaves, Sébastien, Vinzio, Stéphane, Sacré, Karim, Robert, Marie, Comont, Thilbault, Dion, Jérémie, Girardie, Pierre, Lacombe, Valentin, Langlois, Vincent, Jachiet, Vincent, Decker, Paul, Moulinet, Thomas, Grosleron, Sylvie, Broner, Jonathan, Guilpain, Philippe, Samson, Maxime, Terrier, Benjamin, Georgin-Lavialle, Sophie, Attarian, Sharham, Mekinian, Arsène, Delmont, Emilien, Ebbo, Mikael
• Format: Article
• Language: English
• Subjects: Cranial nerves; Encephalopathy; Medicine; Medicine & Public Health; Mutation; Neurology; Neuropathy; Neuroradiology; Neurosciences; Original Communication; Patients; Peripheral nervous system; Polyneuropathy; Steroid hormones; Vacuoles
• ISSN: 0340-5354; 1432-1459
• DOI: 10.1007/s00415-025-12902-x

Background VEXAS syndrome (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) is a recently described syndrome linked to somatic mutations in the UBA1 gene, causing systemic autoinflammatory manifestations. To date, few data are available concerning neurological manifestations. The aim of this study was to describe their prevalence, clinical spectrum and outcome under treatment. Methods Retrospective multicentre study including patients with VEXAS syndrome from the French VEXAS Registry between November 2020 and March 2023. Additional cases were included after a national call for observations. Each patient with confirmed UBA1 somatic mutation and neurological manifestation was reviewed during multidisciplinary meetings. Clinical, radiological, biological characteristics, treatments, and outcome were described. Results Of the 291 patients included in the French VEXAS Registry, 17 (6%) had central (CNS) or peripheral (PNS) neurological involvement, with 13 additional cases identified by the national call. Of the 30 patients included, 21 (70%) had PNS involvement and 9 (30%) CNS involvement. PNS involvements included polyneuropathy ( n = 9), cranial nerve involvement ( n = 7), non-length-dependent polyneuropathy ( n = 5) and multiple mononeuropathy ( n = 3). CNS involvements included encephalopathy ( n = 6), lacunar cerebral infarcts ( n = 4), posterior reversible encephalopathy syndrome ( n = 3) and optic perineuritis ( n = 2). Most neurological manifestations were improved by steroids (68%), steroid-sparing agents were used in 90% [most frequently ruxolitinib ( n = 11), azacitidine ( n = 8), tocilizumab ( n = 4)], and mortality was 30% after a median follow-up of 4 years. Conclusions Neurological manifestations may occur in a small but possibly underestimated proportion of patients with VEXAS syndrome, are heterogeneous and can involve both PNS and CNS.